Agios maintains a robust balance sheet and is positioned for significant growth if regulatory approvals and market expansion ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

Agios Pharmaceuticals (AGIO) announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster ...

Discover key Q3 2025 insights from Agios Pharmaceuticals' earnings call—PYRUKYND progress, revenue growth, global launches, and regulatory updates.

PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia ...

Research and Development (R&D) Expenses were $86.8 million for the third quarter of 2025, an increase of $14.3 million compared to the third quarter of 2024. The year-over-year increase was primarily ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Did you miss out on key UPSC current affairs tidbits? Here's a quick checklist of must-know facts — learn about new ASEAN ...

Abstract: Deep learning technology has made significant strides in diagnosing various diseases. One of the most crucial factors is selecting the appropriate hyperparameter combination, which can ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...